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a b s t r a c t
The use of calcium phosphate cements (CPC) is restricted by their lack of macroporosity and poor drug
release properties. To overcome these two limitations, incorporating degradable polymer microparticles
into CPC is an attractive option, as polymer microparticles could help to control drug release and induce
macroporosity after degradation. Although few authors have yet tested synthetic polymers, the potenti-
ality of polysaccharides’ assuming this role has never been explored. Low-methoxy amidated pectins
(LMAP) constitute valuable candidates because of their biocompatibility and ionic and pH sensitivity.
In this study, the potentiality of a LMAP with a degree of esterification (DE) of 30 and a degree of amida-
tion (DA) of 19 was explored. The aim of this study was to explore the influence of LMAP microspheres
within the composite on the cement properties, drug release ability and final macroporosity after micro-
spheres degradation. Three LMAP incorporation ratios, 2%, 4% and 6% w/wwere tested, and ibuprofen was
chosen as the model drug. In comparison with the CPC reference, the resulting composites presented
reduced setting times and lowered the mechanical properties, which remained acceptable for an implan-
tation in moderate-stress-bearing locations. Sustained release of ibuprofen was obtained on at least
45 days, and release rates were found to be controlled by the LMAP ratio, which modulated drug diffu-
sion. After 4 months of degradation study, the resulting CPC appeared macroporous, with a maximum
macroporosity of nearly 30% for the highest LMAP incorporation ratio, and interconnectivity between
pores could be observed. In conclusion, LMAP appear as interesting candidates to generate macroporous
bone cements with tailored release properties and macroporosity by adjusting the pectin content within
the composites.
1. Introduction
Calcium phosphate materials have gained clinical acceptance
for bone substitution because of their similarity to the mineral part
of bone and their recognized biocompatibility. Calcium phosphate
cements (CPC) are of particular interest for treating low-load- or
non-load-bearing bone defects because of their moldability and
osteoconductivity. Many compositions have been reported since
the first CPC was developed in 1985 [1]. They all consist in a CP
powder mixed with an aqueous liquid to form a paste which can
conform to osseous defects with complex shapes and set in vivo.
In most of them, the final crystalline phase is hydroxyapatite [2,3].
However, two major drawbacks restrict CPC use. The first is
their slow resorption rate [4,5], attributed to their microporosity,
with pore sizes from submicrometer to a few micrometers [6]. Sev-
eral investigators have studied bone ingrowth into porous mate
rials with different pore sizes, and the consensus seems to be that
the optimal pore size is from 100 lm to more than 300 lm [7]. The
second is their poor ability as drug delivery systems: inclusion of
active compounds into CPC fails to obtain controlled release in
more than 1 week in the absence of specific binding affinity be-
tween the drug and calcium phosphate (see Ref. [8] for a review).
To overcome these two limitations, incorporating degradable poly-
mer microparticles into CPC is an attractive option, as polymer
microparticles could help to control drug release and induce
macroporosity after degradation.
A few authors have already explored this way, using polymer
microspheres either as porogens [9–16] or as drug delivery sys-
tems [17–21]. In most cases, synthetic polymers, mainly poly(lac-
tic-co-glycolic) acid (PLGA), were tested. To the authors’
knowledge, although polysaccharides are frequently added to
CPC as rheological modifiers or cohesion promoters, their ability
to formmicroparticles has never been exploited to generate micro-
spheres–calcium phosphate composite bone cements.
Pectin is a naturally occurring heterogeneous water-soluble
polysaccharide which is found in the cell walls of most plants. It
consists mainly of linearly connected a-(1,4)-D-galacturonic acid
monosaccharide units which may be methyl-esterified or amidated
to varying extents. Low-methoxy (with a degree of esterification
DE <50%) pectins (LMP) and low-methoxy amidated pectins
(LMAP) can gel with an ‘‘egg-box” configuration in the presence
of many divalent cations [22], allowing the formation of micro-
spheres by ionotropic gelation, without use of organic solvents
and harsh ingredients. Pectin is biocompatible, biodegradable
[23] and has recently demonstrated its potential to be used in
the surface modification of medical devices and materials [24,25]
and, in particular, bone implant nanocoatings [26–28].
The authors previously studied the feasibility of introducing
LMP or LMAP microspheres into an apatitic CPC [29]. LMP present-
ing various degrees of esterification (DE) and amidation (DA) were
tested in terms of ability to form microspheres, resistance to ionic
conditions and pH variations occurring in the cement while setting
and hardening, and influence the cement chemical evolution. Pec-
tin DE and DA appeared as key formulation parameters in compos-
ite formulation, as they controlled microsphere swelling and
degradation with time and pH. Some of the LMP tested appeared
suitable for the elaboration of organic–mineral composites whose
drug release and degradation properties remained to be explored.
In this study, it was decided to explore the potentiality of one of
these pectins: a LMAP with DE 30 and DA 19. The aim was to study
the influence of pectin microspheres within the composite on the
cement properties, drug release ability and final macroporosity
after microsphere degradation. To do so, three LMAP incorporation
ratios, 2%, 4% and 6% w/w were tested. The resulting composites
were characterized in terms of setting times and mechanical prop-
erties in order to ensure their suitability for implantation. To study
the composite’s release properties, ibuprofen, a non-steroidal anti-
inflammatory drug, was chosen as the model drug. Drug release
from the composites was followed for 45 days and compared with
releases from the microspheres and CPC reference. Then the degra-
dation study was pursued for 2.5 months, and the resulting CPC
studied in term of macroporosity.
2. Materials and methods
2.1. Materials
LMAP with DE 30, DA 19, and average molecular weight
228,000 was supplied by CPKelco (Denmark). Extemporaneous
CPC, Cementek™, was kindly supplied by Teknimed (France). The
CPC powder consisted of tetracalcium phosphate (TTCP:
Ca4[PO4]2O; 49%), a-tricalcium phosphate (a-TCP: Ca3[PO4]2;
38%) and sodium glycerophosphate (NaGP: Na2C3H5(OH2)PO4;
13%). The acidic liquid phase was prepared from lime (Ca(OH)2;
32%) and phosphoric acid (H3PO4; 68%). After mixing the two
phases, with a liquid to powder weight ratio of 0.43, a succession
of acidic–basic reactions of dissolution–precipitation took place, fi-
nally giving hydroxyapatite with an atomic ratio Ca/P of 1.635. Ibu-
profen was acquired from Merck (Germany). All other chemicals
used in this study were of analytical grade.
2.2. Preparation of LMAP microspheres
Solutions of 3% w/v LMAP were prepared by dispersing pectin
into phosphate buffer, pH 8. LMAP microspheres were produced
by ionotropic gelation using an electrostatic bead generator (Ino-
tech encapsulator IE 50 R, Switzerland) equipped with a syringe
pump and a 300 lm nozzle. The pectin solutions were dropped
into a solution of CaCl2 500 mM (cross-linking solution) under con-
tinuous agitation. The gelled microspheres, instantaneously
formed, were allowed to cure in the cross-linking solution for
24 h. Then they were separated by filtration, washed with de
ionized water, dehydrated in a graded series of ethanol, and dried
for 48 h at 37 °C. In order to test the release properties of LMAP
microspheres, ibuprofen LMAP (IBU–LMAP) microspheres were
also prepared according to the same protocol, with ibuprofen
added within the pectin solutions at the beginning of preparation.
2.3. Characterization of LMAP microspheres
Particle size distributions were measured using a laser particle
sizer (Mastersizer 2000; Malvern, UK) based on a laser light-scat-
tering technique. Each sample was measured in triplicate. The
weight average of volume distribution (D[4;3]) was used to
describe the particle size.
The morphology (shape and surface) of the microspheres was
analyzed by scanning electron microscopy (SEM) using a JEOL
scanning electron microscope (JSM-6400F) at 15 kV. Samples were
coated with silver under vacuum by a SPI sputter coating unit.
2.4. Preparation of CPC and CP–LMAP microspheres composites
The powder and liquid phase of the cement were mixed for
2 min, then the required amount of dry microspheres (ranging
from 0% to 6% w/w of the final mass of the composites) was added
and mixed until homogenous repartition of the microparticles
within the paste was obtained. The paste was then filled into cylin-
drical molds and treated further according to the assays.
2.5. Characterization of CPC and CP–LMAP microspheres composites
Setting times of CPC and composites were determined into of
1.25 cm3 with a TA-XT2 Texture analyzer equipped with a needle
(0.7 mm in diameter). It was considered that the cement had set
when the paste developed a resistance to needle penetration of
over 600 g mmÿ2.
The compressive strength of the composites was evaluated with
a computed controlled Hounsfield series S apparatus. Tests were
conducted in air, on wet specimens (10 mm in diameter and
20 mm high) after 7 days in a saturated atmosphere at 37 °C.
2.6. In vitro drug release studies
2.6.1. Drug loading and encapsulation efficiency
The drug loading and encapsulation efficiency were determined
after complete degradation of LMAP microspheres in pH 8 phos-
phate buffer. The ibuprofen content of the microspheres was as-
sayed by UV spectrophotometry (Perkin-Elmer, USA) at 222 nm.
The determinations were performed in triplicate. The drug loading
and encapsulation efficiency were calculated according to the fol-
lowing equations, respectively:
drug loading ¼ ½AQ=ðtotal weight of microspheres by batchÿ AQÞ  100
ð1Þ
encapsulation efficiency ðdrug entrapment ability in %Þ ¼ ðAQ=TQÞ  100
ð2Þ
where AQ is the actual quantity of drug present in the matrices
(drug content), and TQ is the theoretical quantity of drug (initial
ibuprofen loading dose during preparation of the microspheres).
2.6.2. Ibuprofen release from microspheres, CPC and composites under
in vitro conditions
Ibuprofen release was performed in SBF, pH 7.25, prepared
according to Kokubo and Takadama [30]. Standards methods of re-
lease experiments in pharmacopoeias are hardly suitable for multi-
particulate dosage forms, due to the large volumes of the vessels; a
modified alternative method, proposed by research groups work-
ARTICLE IN PRESS
ing on multi-particulate dosage forms for colon delivery, was used
[31]. Briefly, composites (containing IBU–LMAP microspheres at a
weight ratio of 2%, 4% and 6%, leading to composites with an
increasing drug loading of 2, 4 and 6 mg, respectively) or CPC spec-
imens (accurate weight 2.5 g) or IBU–LMAP microspheres (accu-
rate weight 100 mg corresponding to the weight of microspheres
incorporated into CP–LMAP 4% composites) were placed in test
tubes containing 15 ml of SBF, pH 7.25, at 37 °C under agitation
at 100 rpm. Five milliliters of dissolution medium were collected
at various time intervals up to 45 days, and the ibuprofen released
was assayed spectrophotometrically (Perkin-Elmer, USA) at
222 nm. All UV measurements were performed with a double
beam apparatus against a blank of SBF. The release study was con-
tinued after replacement of 5 ml of fresh buffer. Cumulated
amounts released (in percentages of the initial amounts) were
plotted vs time. Each in vitro release study was performed four
times. All the studies were performed under sink conditions for
ibuprofen.
2.7. Porosity measurements
Samples that had been immersed for 4 months in SBF, pH 7.25,
were used to measure the final density and porosity of the compos-
ites. Results were obtained using the method previously described
by Xu et al. [32]. Briefly, the specimens were polished and dried
until their mass remained stable. The density of the materials
was measured using the specimen mass divided by its volume,
which was calculated by the specimen dimensions measured with
a micrometer. Xu showed that this method yielded a density which
closely matched values measured by a mercury intrusion method.
Four specimens were measured for each material. Composites con-
sisted of intrinsic microporosity and additional macroporosity
from microsphere degradation. The total porosity Ptotal of the spec-
imen can be obtained by
Ptotal ¼ ðdHA ÿ dmeasuredÞ=dHA ð3Þ
where dHA is the density of a fully dense hydroxyapatite which is
3.14 g cmÿ3, and dmeasured is the measured density at a specific
LMAP mass fraction. The macropore volume fraction from LMAP
microsphere degradation Ppectin microspheres can be obtained by
Ppectinmicrospheres ¼ 1ÿ dmeasured=dmeasuredÿ0% ð4Þ
where dmeasured is the measured density of specimen with a specific
LMAP content and dmeasured–0% is the measured density of CPC refer-
ence with 0% LMAP.
2.8. Statistical analysis
Results are expressed as means and standard deviations of at
least five experiments. ANOVA one-way analysis was performed
to detect significant effects of material composition on the setting
time or mechanical properties of the resulting composites. Tukey’s
comparison test was used to compare the data. Probability values
p 6 0.05 were considered significant.
3. Results and discussion
3.1. LMAP microspheres preparation and characterization
Based on previous results, a LMAP with a DE of 30 and a DA of
19 was chosen because its microspheres maintained their multi-
particulate structure under pH variations mimicking those occur-
ring in the cement while setting and hardening, and showed mod-
erate swelling ability, considered of good prognostic in obtaining
further sustained drug delivery and controlled erosion/degradation
with time and pH [29].
As a first step, LMAP microspheres alone or loaded with ibupro-
fen (IBU–LMAP) were prepared by ionotropic gelation in the pres-
ence of calcium ions. Gelled microspheres were obtained
instantaneously when LMAP solutions were dropped into a cal-
cium bath. Intermolecular cross-links were formed between the
negatively charged carboxyl groups of LMAP and the positively
charged counter-ions, as previously described by Grant et al. [22]
in the ‘‘egg-box model”. After drying, the resulting microspheres
were characterized in terms of size distribution and morphology,
with the aim of investigating the potential influence of the addition
of ibuprofen. Loaded and unloaded LMAP microspheres with a
weight average of volume distribution D[4;3] of 280 lm and
265 lm, respectively, were obtained, with monomodal and narrow
particle size distribution (polydispersity index 0.69 and 0.68,
respectively). The drug presence did not show a significant influ-
ence on the particle size distributions. The microspheres appeared
very similar, spherical to ovoid with a smooth surface, when ob-
served by SEM (Fig. 1). In the case of IBU–LMAP microspheres, no
crystals were observed at the particles’ periphery, showing that
ibuprofen was completely encapsulated within the microsphere
structure and not only adsorbed on their surface.
3.2. Physico-chemical characterization of CP–LMAP microspheres
composites
LMAP microspheres from 2% to 6% w/w were incorporated into
extemporaneous CPC. Previous formulation tests have shown that
those incorporation ratios allowed composites with maintained
malleability and cohesion to be obtained. The influence of LMAP
weight ratio on the setting and mechanical properties of the com-
posites was studied.
Fig. 2 displays the setting times of the composites according to
their LMAP microsphere weight ratio. One-way ANOVA identified
significant effects of LMAP incorporation ratios of 4% w/w or higher
Fig. 1. SEM photographs of LMAP microspheres: (A) LMAP microspheres; (B) LMAP microspheres loaded with ibuprofen (IBU–LMAP).
(p < 0.05). The setting times of composites containing 4% and 6%
LMAP (CP–LMAP4% and CP–LMAP6%) were significantly lower than
that of the CPC control, while composites with 2% LMAP micro-
spheres (CP–LMAP2%) showed no statistical difference with CPC
control (22.3 ± 0.8 min). The setting times of CP–LMAP4% and
CP–LMAP6% (11.7 ± 2.9 min and 10.9 ± 4.1 min, respectively) were
not significantly different from each other, but CP–LMAP6% com-
posites presented higher standard deviations due to their higher
heterogeneity. However, whatever their LMAP content, the setting
times of the composites remained compatible with a surgical
implantation. The shortening of composite setting times for LMAP
ratios >2% w/w can be attributed to LMAP microspheres’ swelling
properties, as they were added in a dry state to the extempora
neous CPC. It can be assumed that part of the liquid phase of the
cement was absorbed by the microspheres, lowering the amount
of liquid available for CPC setting, and hence its setting time. None-
theless, SEM observations of the composites 1 h after preparation
evidenced the presence of leaflet-shaped crystals characteristic of
the formation of brushite (dicalcium phosphate dihydrate) in all
of them, clearly showing that LMAP microspheres did not hamper
the entanglement of calcium phosphate crystals and the setting
reaction. This was confirmed by X-ray diffraction analysis (data
not shown).
Fig. 3 plots the compressive strength vs composites’ LMAP con-
tent. One-way ANOVA identified the significant effects of LMAP ra-
tios (p < 0.01). For each LMAP ratio, the strength of the CP–LMAP
composite was significantly lower than that of the CPC control
(5.78 ± 0.12 MPa; p < 0.05). The strength of CP–LMAP4% and of
CP–LMAP6% (3.53 ± 0.47 MPa and 2.40 ± 0.90 MPa, respectively)
were not significantly different from each other, but significantly
lower than the strength of CP–LMAP2%. These results are not sur-
prising, as previous studies on the mechanical strength of CP–poly-
mer (PLGA) microsphere composite scaffolds in vitro showed that
the initial strengths of the composite scaffolds were significantly
lower than for CPC alone [20]. This is not problematic, as CPC use
is limited to low-stress-bearing locations [2]. Nonetheless, the
CP–LMAP composites’ strength values still overlap the compressive
strength of 2–12 MPa reported for cancellous bone [33]. Moreover,
the initial decrease in mechanical strength of CP–polymer micro-
spheres composites should be compensated with implantation
time in vivo by bone ingrowth into the composites [11].
The results showed a significant influence of pectin incorpora-
tion ratio on the composites properties. However, in the range of
LMAP ratios tested, the composites obtained presented setting
times, chemical evolutions and mechanical properties compatible
with surgical implantation. No significant differences were ob-
served between ibuprofen-loaded and unloaded CP–LMAP
composites.
3.3. Ibuprofen release from CP–LMAP microspheres composites under
in vitro conditions; comparison with LMAP microspheres and CPC
control
The composites’ in vitro drug release properties were evaluated
for 45 days in SBF, pH 7.25, at 37 °C, in order to mimic the ionic
conditions encountered when implanted in vivo [30]. Ibuprofen
was chosen as the model drug because of its hydrophobicity and
higher solubility at basic pH (it is a weak acid with pKa 4.5), allow-
ing study of the release of a drug able to diffuse freely out of the
composites without presenting specific interactions with CP or
LMAP. In the operating conditions, an encapsulation efficiency of
77% and a drug loading of 4% of ibuprofen into LMAP microspheres
were obtained. Obtaining better entrapment efficiency was not the
purpose of the study, but it could be optimized by playing with the
counter-ion type and concentration, with the pH of the cross-
linking baths and with the composition of the rinsing solutions be-
fore drying [34]. Dry IBU–LMAP microspheres were incorporated
into CPC at weight ratios of 2%, 4% and 6%, leading to composites
with an increasing drug loading. Release patterns were presented
by plotting the cumulated percentage of ibuprofen released vs
time.
Fig. 4 displays the release profiles of ibuprofen according to the
LMAP microspheres ratio in the composites. They were almost
identical in shape, presenting a very limited initial burst in the ini-
tial 24 h (see Table 1), followed by slow and sustained drug release.
The release data were simulated using Higuchi theory, which
investigated whether the ibuprofen cumulative release percent-
ages from composites were proportional to the square root of time.
They correlated well with this model, as shown in Table 1 by the
coefficient of determination of the linear plots obtained, demon-
strating that ibuprofen was released by Fickian diffusion from all
the composites. But surprisingly, different release rates were ob-
tained according to the LMAP microspheres ratio into the compos-
ites, in the order CP/IBU–LMAP2% > CP/IBU–LMAP4% > CP/IBU–
LMAP6%. Differences in cumulated ibuprofen release became more
apparent as time progressed towards the end of the in vitro study,
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Fig. 2. Setting time of CP–LMAP composites as a function of LMAP incorporation
ratio; comparison with CPC reference. The same number of asterisks above the
histograms indicates values that are not significantly different (Tukey’s multiple
comparison test at p = 0.05).
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Fig. 3. Compressive strengths of CP–LMAP composites after 7 days in a saturated
atmosphere at 37 °C as a function of LMAP incorporation ratio; comparison with
CPC reference. The same number of asterisks above histograms indicates values that
are not significantly different (Tukey’s multiple comparison test at p = 0.05).
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clearly showing that the IBU–LMAP content significantly affected
drug release.
Two hypotheses can be proposed to explain this phenomenon.
First, even if perfect sink conditions were maintained throughout
the experiments, the confinement of the drug within the compos-
ites must be taken in account. Locally, the drug concentration
might have exceeded its solubility and slowed its diffusion out of
the cement matrix. But another possible explanation is that LMAP
controlled drug release within the composites. Such phenomenon
can be related to what was observed by Weir and Takechi when
they directly added polysaccharides, namely alginate [35] or chito-
san [36,37], into CPC. They established that the release rate of the
drug was slowed proportionally to the amount of polysaccharide
present in the cement, at least at the beginning of their release
studies. They attributed this slowing down to the gel-forming abil-
ities of the polysaccharides which could block some of the intrinsic
pores in CPC, thus reducing the porosity responsible for drug re-
lease. LMAP microspheres could have operated according to the
same mechanism and regulated the diffusion of ibuprofen out of
the composites.
In order to confirm this, releases of the same amount of ibupro-
fen from a CP–LMAP composite, a CPC and LMAP microspheres
were compared under the same experimental conditions. The re-
sults are presented in Fig. 5. While CPC released 100% ibuprofen
within 48 h, clearly showing that there is no interaction between
the cement and the drug, composite and microsphere release pat-
terns presented the same shape, demonstrating that LMAP micro-
spheres controlled ibuprofen release from composites. Such
sustained release can be explained by LMAP microspheres’ sensi-
tivity to ionic conditions. They behave as hydrophilic matrices
whose release ability is currently related to their swelling ability
in dissolution media [34]. The presence of calcium in the LMAP sur-
rounding (in SBF medium and CPC in this case) has been shown to
enhance cross-linking and aggregation of the pectin chains [38],
thus limiting swelling patterns and, subsequently, drug release
from microspheres and composites. In the case of CP–LMAP micro-
spheres composites, the release rate of ibuprofen was even more
slowed. This can be attributed to additional drug diffusion through
the cement pores partially blocked by LMAP microspheres.
3.4. Porosity measurements of composites
Specimens that had been immersed for 4 months in SBF, pH
7.25, were used to measure the final density and porosity of the
CP–LMAP composites using Eqs. (3) and (4). The values obtained
are reported in Table 2. All formulations maintained their integrity
during the study. LMAP microspheres succeeded in creating
macroporosity in the cement. When the LMAP microsphere ratio
increased from 0% to 6% w/w, the CP–LMAP composites density de-
creased from 1.57 ± 0.04 g cmÿ3 to 1.11 ± 0.06 g cmÿ3. Total poros-
ity increased from 50% to 65%, and macroporosity reached nearly
30%. Porosities obtained were much lower than those of porous
ceramics currently available for bone regeneration. However, some
studies have demonstrated that a gain in macroporosity, even lim-
ited, should be sufficient to improve CPC resorption and that mac-
ropore size and shape, together with scaffold geometry, constitute
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Fig. 4. Ibuprofen in vitro release from composites in SBF, pH 7.25 (N, CP/IBU–
LMAP6% composite;j, CP/IBU–LMAP4% composite; , CP/IBU–LMAP2% composite).
Table 1
Kinetic analysis of ibuprofen release from CP–LMAP microspheres composites and LMAP microspheres.
Cumulated ibuprofen released
within the first 24 h (%)
Cumulated ibuprofen released
after 45 days (%)
Higuchi model coefficient
of determination r2 (%)
Higuchi dissolution constant
kH (10
ÿ2 hÿ1/2)
CP/IBU–LMAP2% 11.9 ± 0.2 69.1 ± 5.5 99.0 2.2
CP/IBU–LMAP4% 9.1 ± 0.5 47.4 ± 3.0 99.5 1.5
CP/IBU–LMAP6% 6.7 ± 0.9 31.8 ± 2.9 98.9 1.0
IBU–LMAP microspheres 14.6 ± 1.1 61.9 ± 1.9 99.4 1.8
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Fig. 5. Ibuprofen in vitro release from composites in SBF, pH 7.25, comparison with
the same quantity of ibuprofen (4 mg) encapsulated into LMAP microspheres or
directly incorporated into CPC reference (d, IBU–LMAP microspheres; j, CP/IBU–
LMAP4% composite; ., IBU–CPC).
Table 2
Density, total porosity and macroporosity of CP–LMAP composites vs LMAP incor-
poration ratio, after 4 months in SBF, pH 7.25 (the scaffolds density (mean ± SD; n = 4)
was measured as described in Section 2; total porosity and macroporosity were
calculated using Eqs. (3) and (4), respectively).
LMAP weight
fraction (%)
Density
(g cmÿ3)
Total pore volume
fraction (%)
Macropore volume
fraction (%)
0 1.57 ± 0.04 50.1 ± 1.4 0
2 1.39 ± 0.03 55.8 ± 0.9 11.5 ± 1.9
4 1.20 ± 0.04 61.6 ± 1.3 23.1 ± 2.7
6 1.11 ± 0.06 64.7 ± 1.8 29.2 ± 3.6
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non-negligible parameters which can affect the threshold for inter-
connectivity and hence cement colonization [15]. Moreover, CP–
pectin composite formulation could easily be optimized by modi-
fying the pectin type. Choosing a pectin presenting lower swelling
properties, i.e. with decreased DE and/or DA, would permit to en-
hance the pectin mass fraction in the composites, and thus final
macroporosity, but would also result in reduced drug release abil-
ity and longer microsphere degradation time. A compromise must
be found to adjust on-demand composite properties in terms of
delivery and final macroporosity.
Fig. 6 displays SEM micrographs of the inner surface of broken
composites (Fig. 6B–D) to compare with the CPC control
(Fig. 6A). Cross sections suggest a homogeneous distribution of
microparticles throughout the scaffolds in all formulations.
Whereas on the CPC control only micropores can be seen, well-
formed macropores with the shape of the entrapped microspheres
can be observed within the composites. The macropores created
present sizes suitable for promoting cell infiltration and bone in-
growth [7]. In CP–LMAP2% composites, these macropores appear
neighbouring but separated, whereas for CP–LMAP4% and CP–
LMAP6%, some interconnections can be observed between the
macropores. Fig. 6C is a micrograph of a typical CP–LMAP4% com-
posite; an arrow indicates an open connection at the bottom of a
macropore. Moreover, as can be seen in Fig. 6D (CP–LMAP6% com-
posites), pectin microsphere swelling induced microcracks within
the CP cement structure, generating additional interconnections
between macropores, indicated by arrows.
Although the macropores formed by degradation of the pectin
microspheres did not form a fully interconnected network in the
case of the lowest LMAP ratios, tissue ingrowth throughout the
scaffold should remain possible, as the microporosity and even
nanoporosity of CPC also play an important role over small dis-
tances, as shown by Ruhe et al. [12] during his study on PLGA
microspheres–CPC composites. As a consequence, the macropores
induced by LMAP microspheres degradation are expected to en-
hance the composite’s resorption rate in comparison with the con-
trol CPC. The exact gain has to be evaluated by an in vivo test, but
the first results presented in this study appear promising.
4. Conclusion
To our knowledge, no previous studies concerning CP–pectin
microspheres composite materials have been published. The incor-
poration of LMA pectin microspheres within a CPC led to organic–
mineral composites with original properties, suitable for implanta-
tion in moderate-stress-bearing locations. In term of drug delivery,
sustained release of ibuprofen was obtained on more than 45 days,
and the LMAP ratio appeared to be a key parameter regulating drug
diffusion. By adjusting their pectin microsphere content it should
be possible to design tailorable composites whose release rates
could be controlled upon demand. With time, the microspheres
progressively degraded, creating a macroporous CPC scaffold im-
plant expected to present an enhanced resorption rate and faster
cell colonization. The results of this first in vitro evaluation warrant
further investigation of the material’s in vivo behavior. Taking in
account the potentials of these composites for sustained drug
delivery and induced macroporosity, CP–LMAP composites appear
to be a promising scaffolding material for bone regeneration and
bone tissue engineering, with the advantage over CP–PLGA com-
posites that no acidic degradation products were generated.
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